Aripiprazole Tablet
Product Images NDC 27241-052

16 FDA label images from Ajanta Pharma Usa Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 27241-052). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (Aripiprazole Struct)

Structure (Aripiprazole Struct)
Chemical structure of Aripiprazole, showing its molecular arrangement including chlorine atoms, piperazine ring, and quinolinone moiety, consistent with the active ingredient in Aripiprazole tablets.*
FDA Label Image

Aripiprazole_fig_01 (Aripiprazole Fig 01)

Aripiprazole_fig_01 (Aripiprazole Fig 01)
A scatter plot chart titled 'Effect of Other Drugs on Aripiprazole' showing Aripiprazole fold change and 90% confidence intervals for various interacting drugs. The x-axis shows change relative to reference without interacting drug, ranging from 0.5 to 3.0, and the y-axis lists drug types categorized as CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and others with corresponding pharmacokinetic parameters AUC and Cmax.*
FDA Label Image

Aripiprazole_fig_02 (Aripiprazole Fig 02)

Aripiprazole_fig_02 (Aripiprazole Fig 02)
A chart showing the effect of various drugs on Aripiprazole pharmacokinetics, specifically the dehydro-aripiprazole fold change and 90% confidence intervals for AUC and Cmax values. Drugs listed include CYP3A4 inhibitors and inducers, CYP2D6 inhibitor, gastric acid blockers, and others, with changes relative to a reference without interacting drug plotted on the x-axis.*
FDA Label Image

Aripiprazole_fig_03 (Aripiprazole Fig 03)

Aripiprazole_fig_03 (Aripiprazole Fig 03)
A forest plot chart showing the effect of Aripiprazole on the pharmacokinetics of various drugs, including dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The chart illustrates fold change and 90% confidence intervals for parameters like AUC and Cmax compared to reference values without interacting drugs.*
FDA Label Image

Figure4 (Aripiprazole Fig4)

Figure4 (Aripiprazole Fig4)
A graph titled 'Aripiprazole Fold Change and 90% CI' showing the pharmacokinetic (PK) parameters AUC and Cmax across special populations, including CYP2D6 metabolizer status, gender, age, hepatic impairment levels, and severe renal impairment. The x-axis represents change relative to reference values on a scale from 0.5 to 3.0 with data points indicating fold changes and confidence intervals.*
FDA Label Image

Figure5 (Aripiprazole Fig5)

Figure5 (Aripiprazole Fig5)
A forest plot showing the fold change and 90% confidence intervals for Dehydro-Aripiprazole pharmacokinetics. The chart compares AUC and Cmax values relative to reference across categories such as CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment.*
FDA Label Image

Figure6 (Aripiprazole Figure6)

Figure6 (Aripiprazole Figure6)
A clinical trial survival curve chart comparing the proportion of subjects with relapse over 182 days from randomization for Aripiprazole versus placebo. The vertical axis represents the proportion with relapse, and the horizontal axis represents days from randomization. The chart also shows the number of subjects at risk for each group over time intervals.*
FDA Label Image

Figure7 (Aripiprazole Figure7)

Figure7 (Aripiprazole Figure7)
A Kaplan-Meier curve graph comparing the proportion of relapse over time in subjects treated with Aripiprazole versus placebo. The x-axis represents days from randomization (0 to 182 days), and the y-axis represents the proportion with relapse (0.0 to 1.0). Two curves show lower relapse proportion in Aripiprazole group compared to placebo. The number of subjects at risk is provided below the x-axis for both groups at various time points.*
FDA Label Image

Figure8 (Aripiprazole Figure8)

Figure8 (Aripiprazole Figure8)
A line graph showing the proportion of subjects with relapse over days from randomization, comparing Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The graph includes the number of subjects at risk below the x-axis for each group at multiple time points.*
FDA Label Image

Figure9 (Aripiprazole Fig9)

Figure9 (Aripiprazole  Fig9)
A line graph showing change in YGTSS total tic score from baseline over 8 weeks of treatment. The graph compares three groups: Aripiprazole low dose, Aripiprazole high dose, and placebo, with Y-axis representing least-squares mean change in tic score and X-axis representing weeks of treatment.*
FDA Label Image

2mg (Aripiprazole 2mg)

2mg (Aripiprazole 2mg)
Packaging label for Aripiprazole Tablets USP 2 mg oral tablets, containing 30 tablets per package. The label states it is a prescription drug manufactured by Ajanta Pharma Limited, India, and marketed by Ajanta Pharma USA Inc., Bridgewater, NJ. It includes storage instructions, a lot and expiration date area, and a barcode.*
FDA Label Image

5mg (Aripiprazole 5mg)

5mg (Aripiprazole 5mg)
Label for Aripiprazole Tablets USP 5 mg in a 30-tablet package. Manufactured by Ajanta Pharma Limited, India, and marketed by Ajanta Pharma USA Inc. The label includes storage instructions, a barcode, and a note for pharmacists to dispense the enclosed Medication Guide.*
FDA Label Image

10mg (Aripiprazole 10mg)

10mg (Aripiprazole 10mg)
Label for Aripiprazole Tablets USP 10 mg, a prescription oral tablet product. The label indicates packaging of 30 tablets, manufactured by Ajanta Pharma Limited, India, and marketed by Ajanta Pharma USA Inc. It includes storage instructions, a barcode, and space for lot and expiration dates. The label emphasizes child-resistant packaging and pharmacist dispensing guidance.*
FDA Label Image

15mg (Aripiprazole 15mg)

15mg (Aripiprazole 15mg)
Aripiprazole Tablets USP 15 mg tablet label showing package quantity of 30 tablets. The label indicates the product is child-resistant and to be stored at controlled room temperature. Manufacturer is Ajanta Pharma Limited, India and marketed by Ajanta Pharma USA Inc. Includes NDC 27241-054-03 and barcode.*
FDA Label Image

20mg (Aripiprazole 20mg)

20mg (Aripiprazole 20mg)
Packaging label for Aripiprazole Tablets, USP 20 mg, oral tablets. The label indicates the package contains 30 tablets and includes storage instructions at controlled room temperature. Manufactured by Ajanta Pharma Limited, India, and marketed by Ajanta Pharma USA Inc. The label features the NDC 27241-055-03, a barcode, and a note to dispense the enclosed medication guide to patients.*
FDA Label Image

30mg (Aripiprazole 30mg)

30mg (Aripiprazole 30mg)
Aripiprazole Tablets, USP 30 mg tablet label by Ajanta Pharma USA Inc. The label indicates a package of 30 tablets, manufactured by Ajanta Pharma Limited, India. It includes storage instructions for controlled room temperature and warnings to keep out of reach of children. The label also has an NDC (27241-056-03), barcode, and a space for lot and expiration dates.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.